Form 4: Guardant Health Chief Legal Officer Reports Routine Stock Transactions

Guardant Health's Chief Legal Officer, John G. Saia, reported the acquisition of 263 common shares through RSU vesting and the disposition of 138 shares for tax withholding purposes.

Summary

• John G. Saia, the Chief Legal Officer of Guardant Health, Inc. (GH), filed a Form 4 detailing stock transactions that occurred on June 1, 2025.
• Mr. Saia acquired 263 shares of Guardant Health common stock through the vesting of Restricted Stock Units (RSUs) at a price of $0.
• Concurrently, 138 shares were disposed of at a price of $40.62 per share to satisfy tax withholding obligations related to the RSU vesting.
• Following these reported transactions, John G. Saia beneficially owns 43,083 shares of Guardant Health common stock.
• The Restricted Stock Unit award, from which these shares vested, was originally granted on November 2, 2021, with 25% vesting on September 1, 2022, and the remaining 75% vesting in equal installments on each quarterly anniversary thereafter for a three-year period.

Sentiment

Score: 5

Explanation: Neutral, as this is a routine insider transaction related to executive compensation and tax obligations, not indicative of company performance or strategic shifts.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future outlook.

Management Comments

• Shares were retained by the Company to meet the tax withholding obligations of the award-holder in connection with the vesting of an installment of the restricted stock units.
• The amount retained by the Company was not in excess of the amount of the tax liability.

Industry Context

This filing reports a routine insider transaction related to executive compensation, specifically the vesting of Restricted Stock Units and the subsequent disposition of shares for tax purposes. Such transactions are common across publicly traded companies as part of their executive compensation plans and do not typically reflect broader industry trends or competitive positioning.

Stakeholder Impact

• Shareholders may note the ongoing executive compensation activity and the structure of RSU vesting, which is a standard component of executive remuneration.

Next Steps

• Continued quarterly vesting of remaining Restricted Stock Units as per the original award schedule until the full award is vested.

Key Dates

Keywords

Guardant Health, GH, SEC Form 4, Insider Transaction, Restricted Stock Units, RSU Vesting, Executive Compensation, Stock Ownership